Exactech, Inc.

Investigation of Potential Stockholder Action Concerning Exactech, Inc. (Nasdaq: EXAC) Kessler Topaz Meltzer & Check, LLP is investigating a potential stockholder action on behalf of current shareholders of Exactech, Inc. (“Exactech”).

About Exactech

Exactech develops, manufactures, markets, distributes and sells orthopedic implant devices and related surgical instrumentation.  On December 4, 2017, TPG Capital and Exactech announced that they had entered into a merger agreement to take Exactech private.  Pursuant to the merger agreement, Exactech shareholders are expected to be cashed out of their Exactech stockholdings for $49.25 per share.

Alleged Wrongful Conduct

Kessler Topaz Meltzer & Check, LLP is investigating potential breaches of fiduciary duties by members of Exactech Board of Directors, including actions taken by the company’s directors in connection with the sale of Exactech to TPG Capital, which may have caused harm to the company and its current stockholders.

If you currently own shares of Exactech (Nasdaq: EXAC), and would like to learn more about our investigation, please fill out our online form or contact us today at 888-299-7706 or [email protected].

Free Consultation Request

    Personal Information
    * denotes required fields